The ALK anticancer drug Alecensa is anticipated to receive approval for an additional indication as an adjuvant therapy for treating lung cancer.

Sources said that the review for indication approval by the Ministry of Food and Drug Safety (MFDS) is in its final stage for Alecensa (alectinib), Roche Korea's anaplastic Lymphoma Kinase (ALK)- targeted anticancer agent, as a post-operative adjuvant therapy for patients with early-stage non-small cell lung cancer (NSCLC).

The indication of Alecensa has been approved worldwide, including by the U.S. FDA in April and the European Commission (EC).

The basis of indication for the adjuvant therapy for early-stage NSCSC was the Phas